(CCLD) CareCloud - Ratings and Ratios
Cloud Medical, Practice Management, Billing Software, Analytics
CCLD EPS (Earnings per Share)
CCLD Revenue
Description: CCLD CareCloud
CareCloud Inc. (NASDAQ:CCLD) is a US-based company operating in the Health Care Equipment sub-industry. To understand its financial health, we need to examine its income statement, particularly the yearly Income Tax Expense. A thorough analysis of this component can reveal the companys tax strategy and its impact on profitability.
From a fundamental perspective, CareClouds market capitalization stands at $110.04 million, indicating a relatively small-cap stock. The forward Price-to-Earnings ratio is 8.97, suggesting that investors have certain expectations for the companys future earnings growth. Return on Equity (RoE) is 21.82%, which is a positive indicator of the companys ability to generate profits from shareholders equity.
To further assess CareClouds performance, key economic drivers such as revenue growth, operating margins, and cash flow generation should be examined. Important KPIs to monitor include the companys ability to maintain a healthy balance between revenue expansion and expense management, as well as its capacity to invest in research and development to drive future growth. Additionally, metrics like Days Sales Outstanding (DSO) and the Current Ratio can provide insights into the companys working capital management and liquidity position.
From an investment perspective, its crucial to evaluate CareClouds competitive positioning within the healthcare technology sector, its customer base, and the overall demand for its products or services. An analysis of the companys management team, their track record, and the effectiveness of their strategic initiatives can also provide valuable insights into potential future performance.
CCLD Stock Overview
| Market Cap in USD | 146m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2014-07-23 |
CCLD Stock Ratings
| Growth Rating | -31.4% |
| Fundamental | 78.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 3.53% |
| Analyst Rating | 3.50 of 5 |
CCLD Dividends
Currently no dividends paidCCLD Growth Ratios
| Growth Correlation 3m | 76.2% |
| Growth Correlation 12m | -21% |
| Growth Correlation 5y | -81.5% |
| CAGR 5y | -11.02% |
| CAGR/Max DD 3y | -0.13 |
| CAGR/Mean DD 3y | -0.24 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 0.29 |
| Beta | 0.666 |
| Volatility | 81.34% |
| Current Volume | 759.2k |
| Average Volume 20d | 550.8k |
| Stop Loss | 3.1 (-7.5%) |
| Signal | -1.02 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (11.3m TTM) > 0 and > 6% of Revenue (6% = 6.71m TTM) |
| FCFTA 0.30 (>2.0%) and ΔFCFTA 16.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.28% (prev 0.60%; Δ 12.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.33 (>3.0%) and CFO 24.8m > Net Income 11.3m (YES >=105%, WARN >=100%) |
| Net Debt (-7.05m) to EBITDA (25.2m) ratio: -0.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (33.1m) change vs 12m ago 105.3% (target <= -2.0% for YES) |
| Gross Margin 42.98% (prev 34.05%; Δ 8.93pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 149.8% (prev 151.0%; Δ -1.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.69 (EBITDA TTM 25.2m / Interest Expense TTM 373.0k) >= 6 (WARN >= 3) |
Altman Z'' -3.96
| (A) 0.20 = (Total Current Assets 31.1m - Total Current Liabilities 16.2m) / Total Assets 75.2m |
| (B) -0.82 = Retained Earnings (Balance) -61.8m / Total Assets 75.2m |
| (C) 0.15 = EBIT TTM 11.4m / Avg Total Assets 74.6m |
| (D) -3.44 = Book Value of Equity -65.9m / Total Liabilities 19.2m |
| Total Rating: -3.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.88
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 16.22% = 5.0 |
| 3. FCF Margin 20.02% = 5.01 |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda 0.11 = 2.49 |
| 6. ROIC - WACC (= 13.24)% = 12.50 |
| 7. RoE 21.82% = 1.82 |
| 8. Rev. Trend -79.10% = -5.93 |
| 9. EPS Trend 70.08% = 3.50 |
What is the price of CCLD shares?
Over the past week, the price has changed by -4.29%, over one month by +23.16%, over three months by +42.55% and over the past year by +22.71%.
Is CareCloud a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CCLD is around 3.09 USD . This means that CCLD is currently overvalued and has a potential downside of -7.76%.
Is CCLD a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CCLD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.8 | 41.8% |
| Analysts Target Price | 4.8 | 41.8% |
| ValueRay Target Price | 3.4 | 2.7% |
Last update: 2025-09-18 04:32
CCLD Fundamental Data Overview
CCE Cash And Equivalents = 10.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.4251
P/S = 1.3023
P/B = 2.5964
Beta = 2.144
Revenue TTM = 111.8m USD
EBIT TTM = 11.4m USD
EBITDA TTM = 25.2m USD
Long Term Debt = 86.0k USD (from longTermDebt, last quarter)
Short Term Debt = 2.81m USD (from shortTermDebt, last quarter)
Debt = 2.90m USD (Calculated: Short Term 2.81m + Long Term 86.0k)
Net Debt = -7.05m USD (from netDebt column, last quarter)
Enterprise Value = 138.0m USD (145.6m + Debt 2.90m - CCE 10.4m)
Interest Coverage Ratio = 30.69 (Ebit TTM 11.4m / Interest Expense TTM 373.0k)
FCF Yield = 16.22% (FCF TTM 22.4m / Enterprise Value 138.0m)
FCF Margin = 20.02% (FCF TTM 22.4m / Revenue TTM 111.8m)
Net Margin = 10.08% (Net Income TTM 11.3m / Revenue TTM 111.8m)
Gross Margin = 42.98% ((Revenue TTM 111.8m - Cost of Revenue TTM 63.7m) / Revenue TTM)
Tobins Q-Ratio = -2.09 (set to none) (Enterprise Value 138.0m / Book Value Of Equity -65.9m)
Interest Expense / Debt = 2.35% (Interest Expense 68.0k / Debt 2.90m)
Taxrate = 2.00% (160.0k / 8.01m)
NOPAT = 11.2m (EBIT 11.4m * (1 - 2.00%))
Current Ratio = 1.91 (Total Current Assets 31.1m / Total Current Liabilities 16.2m)
Debt / Equity = 0.05 (Debt 2.90m / last Quarter total Stockholder Equity 56.1m)
Debt / EBITDA = 0.11 (Net Debt -7.05m / EBITDA 25.2m)
Debt / FCF = 0.13 (Debt 2.90m / FCF TTM 22.4m)
Total Stockholder Equity = 51.6m (last 4 quarters mean)
RoA = 14.98% (Net Income 11.3m, Total Assets 75.2m )
RoE = 21.82% (Net Income TTM 11.3m / Total Stockholder Equity 51.6m)
RoCE = 22.13% (Ebit 11.4m / (Equity 51.6m + L.T.Debt 86.0k))
RoIC = 21.59% (NOPAT 11.2m / Invested Capital 52.0m)
WACC = 8.35% (E(145.6m)/V(148.5m) * Re(8.47%)) + (D(2.90m)/V(148.5m) * Rd(2.35%) * (1-Tc(0.02)))
Shares Correlation 3-Years: 99.24 | Cagr: 7.37%
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 80.07% ; FCFE base≈17.3m ; Y1≈21.3m ; Y5≈36.3m
Fair Price DCF = 13.44 (DCF Value 568.9m / Shares Outstanding 42.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 70.08 | EPS CAGR: 27.76% | SUE: 0.38 | # QB: 0
Revenue Correlation: -79.10 | Revenue CAGR: -7.30% | SUE: 0.18 | # QB: 0
Additional Sources for CCLD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle